Cloning: Do we even need eggs?
By Phyllida Brown,
Nature
| 02. 09. 2006
Less than a month ago, investigators at Seoul National University in South Korea announced that cloning researcher Woo Suk Hwang had lied when he claimed his team cloned human embryos with relative ease and produced stem cells from them. The news was a significant setback for cloning researchers. In this special section, Nature looks at how biologists are regrouping. Carina Dennis asks how they can get cloning to work given a very limited supply of eggs and Phyllida Brown looks at whether we will need therapeutic cloning at all, if immunologists can stop our bodies fighting transplants (see page 655). And on page 658, one of Hwang's closest rivals admits it may not continue its cloning quest.
see moreNobody likes rejection, but for a transplant patient it can be a death sentence. The risk that a patient's immune system will see a transplanted organ, or graft, as 'foreign' rather than 'self', forces transplant patients on to immunosuppressant drugs that can have severe side effects. Therapeutic cloning, its enthusiasts say, could solve the problem by allowing doctors to grow cells and tissues...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...